KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results